Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6683)
All Articles published online
|
Publishing Process of This Article
|
Aug 18, 2016 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i23/957.htm |
| Number | Citing Articles |
| 1 |
John Porter, Yao Ding, Sarah J.M. Hale, Richard D. Perrins, Angela Robinson, Michael P. Mazanetz, Yubo Wu, Yinping Ma, Kelly Conlon, Tom Coulter. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma. Bioorganic & Medicinal Chemistry Letters 2020; 30(24): 127634 doi: 10.1016/j.bmcl.2020.127634
|
| 2 |
Liming Wang, Weihu Wang, Xuesong Yao, Weiqi Rong, Fan Wu, Bo Chen, Mei Liu, Shengtao Lin, Yunhe Liu, Jianxiong Wu. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion. Oncotarget 2017; 8(45): 79971 doi: 10.18632/oncotarget.20402
|
| 3 |
T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora, D. C. Leucuta. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clinical and Translational Oncology 2019; 21(6): 702 doi: 10.1007/s12094-018-1975-4
|
| 4 |
Chengyun Dou, Hongbo Zhu, Xia Xie, Cuiqin Huang, Hui Tan, Chuangjie Cao. Exosomal circ_0032704 confers sorafenib resistance to hepatocellular carcinoma and contributes to cancer malignant progression by modulating the miR‐514a‐3p/PD‐L1 pathway. Annals of Gastroenterological Surgery 2024; doi: 10.1002/ags3.12772
|
| 5 |
Jian-Hong Zhong, Ning-Fu Peng, Xue-Mei You, Liang Ma, Xiao Xiang, Yan-Yan Wang, Wen-Feng Gong, Fei-Xiang Wu, Bang-De Xiang, Le-Qun Li. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget 2017; 8(11): 18296 doi: 10.18632/oncotarget.15433
|
| 6 |
Chao He, Wei Peng, Chuan Li, Tian-Fu Wen. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine 2017; 96(16): e6606 doi: 10.1097/MD.0000000000006606
|
| 7 |
Muqi Li, Minni Liang, Tian Lan, Xiwen Wu, Wenxuan Xie, Tielong Wang, Zhitao Chen, Shunli Shen, Baogang Peng. Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma. Frontiers in Molecular Biosciences 2020; 7 doi: 10.3389/fmolb.2020.566491
|
| 8 |
Sarah J. M. Hale, Richard D. Perrins, Cristina Espinosa Garcı́a, Alessandro Pace, Usoa Peral, Ketan R. Patel, Angela Robinson, Phil Williams, Yao Ding, Gabriele Saito, Miguel Ángel Rodriguez, Ibon Perera, Africa Barrientos, Kelly Conlon, Steve Damment, John Porter, Tom Coulter. DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma. Bioconjugate Chemistry 2019; 30(3): 703 doi: 10.1021/acs.bioconjchem.8b00873
|